Association of patient-reported pain with survival in bladder cancer: a post-hoc analysis of the iBLAD trial

References

• Dueck AC, Scher HI, Bennett AV, et al. Assessment of adverse events from the patient perspective in a phase 3 metastatic castration-resistant prostate cancer clinical trial. JAMA Oncol. 2020;6(2):e193332.
   PubMed Web of Science ®Google Scholar
• Vodicka E, Kim K, Devine EB, et al. Inclusion of patient-reported outcome measures in registered clinical trials: evidence from ClinicalTrials.gov (2007–2013). Contemp Clin Trials. 2015;43:1–9.
   PubMed Web of Science ®Google Scholar
• EMA. 2014. Reflection paper on the use of patient reported outcome (PRO) measures in oncology studies. Eur Med Agency Sci Med Heal. https://www.ema.europa.eu/en/documents/other/appendix-2-guideline-evaluation-anticancer-medicinal-products-man_en.pdf.
   Google Scholar
• Kluetz PG, Chingos DT, Basch EM, et al. Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the national cancer institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Am Soc Clin Oncol Educ B. 2016;35(1):67–73.
   PubMedGoogle Scholar
• Basch EM, Deal AM, Dueck AC, et al. Overall survival results of a randomized trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. J Clin Oncol. 2017;35(18_suppl):LBA2–LBA2.
   Web of Science ®Google Scholar
• Friis RB, Hjøllund NH, Pappot H, et al. Patient-reported outcome measures used in routine care predict for survival at disease progression in patients with advanced lung cancer. Clin Lung Cancer. 2021;22(2):e169–e179.
   PubMed Web of Science ®Google Scholar
• Nissen A, Bager L, Pappot H. The use of PRO in adverse event identification during cancer therapy–choosing the right questions to ask. Acta Oncol. 2019;58(5):596–602.
   PubMed Web of Science ®Google Scholar
• Riikonen JM, Guyatt GH, Kilpeläinen TP, et al. Decision aids for prostate cancer screening choice: a systematic review and meta-analysis. JAMA Intern Med. 2019;179(8):1072–1082.
   PubMed Web of Science ®Google Scholar
• Mierzynska J, Piccinin C, Pe M, et al. Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review. Lancet Oncol. 2019;20(12):e685–e698.
   PubMed Web of Science ®Google Scholar
• EMA reflection paper on the use of patient reported outcome (PRO) measures in oncology studies. Eur Med Agency Sci Med Heal. 2014;44:1–9.
   Google Scholar
• Tan E, Abuhelwa AY, Badaoui S, et al. Association between patient-reported outcomes and survival in patients with advanced urothelial carcinoma treated with atezolizumab. BLC. 2022;8(1):81–88.
   Google Scholar
• Cella D, Traina S, Li T, et al. Relationship between patient-reported outcomes and clinical outcomes in metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-301 and COU-AA-302. Ann Oncol. 2018;29(2):392–397.
   PubMed Web of Science ®Google Scholar
• Kerrigan K, Patel SB, Haaland B, et al. Prognostic significance of patient-reported outcomes in cancer. J Clin Oncol Pract. 2020;16(4):E313–E323.
   Google Scholar
• Ediebah DE, Quinten C, Coens C, et al. Quality of life as a prognostic indicator of survival: a pooled analysis of individual patient data from Canadian cancer trials group clinical trials. Cancer. 2018;124(16):3409–3416.
   PubMed Web of Science ®Google Scholar
• Quinten C, Coens C, Mauer M, et al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol. 2009;10(9):865–871.
   PubMed Web of Science ®Google Scholar
• Taarnhøj GA. Patient-reported outcomes in bladder cancer. Full text view ClinicalTrials.gov. [cited 2022 Sep 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT03584659?term=iblad&draw=2&rank=1.
   Google Scholar
• Taarnhøj GA. 1556MO – the iBLAD study: patient-reported outcomes in bladder cancer during oncological treatment: a multicenter national randomized controlled trial. In ESMO 2022 mini oral session: supportive and palliative care. Ann Oncol. 2022;33(suppl_7):S713–S742. DOI:10.1016/annonc/annonc1075
   Google Scholar
• Taarnhøj GA, Lindberg H, Johansen C, et al. Patient-reported outcomes item selection for bladder cancer patients in chemo- or immunotherapy. J Patient Rep Outcomes. 2019;3(1):56.
   PubMedGoogle Scholar
• Taarnhøj GA, Lindberg H, Dohn LH, et al. Electronic reporting of patient-reported outcomes in a fragile and comorbid population during cancer therapy – a feasibility study. Health Qual Life Outcomes. 2020;18(1):9.
   PubMed Web of Science ®Google Scholar
• Taarnhøj GA, Lindberg H, Johansen C, et al. Patient-reported outcomes, health-related quality of life, and clinical outcomes for urothelial cancer patients receiving chemo-or immunotherapy: a real-life experience. JCM. 2021;10(9):1852.
   Google Scholar
• Basch E, Reeve BB, Mitchell SA, et al. Development of the national cancer institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J. Natl. Cancer Inst. 2014;106(9):dju244.
   Google Scholar
• Cancer group DB. 2020. Danish national guidelines for treatment of bladder cancer. DaBlaCa
   Google Scholar
• Cathomas R, Lorch A, Bruins HM, et al. The 2021 updated european association of urology guidelines on metastatic urothelial carcinoma. Eur Urol. 2022;81(1):95–103.
   PubMed Web of Science ®Google Scholar
• Hernán MA. The hazards of hazard ratios. Epidemiology. 2010;21(1):13–15.
   PubMed Web of Science ®Google Scholar
• R Core Team. 2020. R Core Team (2020).
   Google Scholar
• de Rooij BH, Ezendam NPM, Mols F, et al. Cancer survivors not participating in observational patient-reported outcome studies have a lower survival compared to participants: the population-based PROFILES registry. Qual Life Res. 2018;27(12):3313–3324.
   PubMed Web of Science ®Google Scholar
• Von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–1457.
   Google Scholar
• World Medical Association. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194.
   PubMed Web of Science ®Google Scholar
• NORDCAN No title. https://nordcan.iarc.fr/en/dataviz/trends?cancers=280&sexes=1_2&populations=208&mode=cancer&multiple_populations=0&multiple_cancers=1.
   Google Scholar
• Antoni S, Ferlay J, Soerjomataram I, et al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71(1):96–108.
   PubMed Web of Science ®Google Scholar
• Witjes JA, Babjuk M, Bellmunt J, et al. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer – an international collaborative multistakeholder effort†[formula presented]: under the auspices of the EAU-ESMO guidelines committees. Eur Urol. 2020;77(2):223–250.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–1026.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Théodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27(27):4454–4461. .
   PubMed Web of Science ®Google Scholar
• Von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068–3077.
   PubMed Web of Science ®Google Scholar
• Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391(10122):748–757.
   PubMed Web of Science ®Google Scholar
• Omland LH, Stormoen DR, Dohn LH, et al. Real-world study of treatment with pembrolizumab among patients with advanced urothelial tract cancer in Denmark. BLC. 2021;7(4):413–425.
   Google Scholar
• Omland LH, Lindberg H, Carus A, et al. Real-world treatment patterns and overall survival in locally advanced and metastatic urothelial tract cancer patients treated with chemotherapy in Denmark in the preimmunotherapy era: a nationwide, population-based study. Eur Urol Open Sci. 2021;24:1–8.
   PubMedGoogle Scholar
• Von Der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602–4608.
   PubMed Web of Science ®Google Scholar
• Mitra AP, Quinn DI, Dorff TB, et al. Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. BJU Int. 2012;109(6):846–854.
   PubMed Web of Science ®Google Scholar
• Ruiz J, Miller AA, Tooze JA, et al. Frailty assessment predicts toxicity during first cycle chemotherapy for advanced lung cancer regardless of chronologic age. J Geriatr Oncol. 2019;10(1):48–54.
   PubMed Web of Science ®Google Scholar
• Stensland KD, Galsky MD. Current approaches to the management of bladder cancer in older patients. Am Soc Clin Oncol Educ B. 2014;e250–e256.
   PubMedGoogle Scholar
• Dómine Gómez M, Díaz Fernández N, Cantos Sánchez de Ibargüen B, et al. Association of performance status and pain in metastatic bone pain management in the Spanish clinical setting. Adv Ther. 2017;34(1):136–147.
   PubMed Web of Science ®Google Scholar
• Henry DH, Viswanathan HN, Elkin EP, et al. Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the U.S. Support Care Cancer. 2008;16(7):791–801.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wu B, Zha Z, et al. Clinicopathological factors in bladder cancer for cancer-specific survival outcomes following radical cystectomy: a systematic review and meta-analysis. BMC Cancer. 2019;19(1):13.
   PubMedGoogle Scholar
• Lin CC, Lai YL, Ward SE. Effect of cancer pain on performance status, mood states, and level of hope among Taiwanese cancer patients. J Pain Symptom Manage. 2003;25(1):29–37.
   PubMed Web of Science ®Google Scholar
• Seow H, Barbera L, Sutradhar R, et al. Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. J Clin Oncol. 2011;29(9):1151–1158.
   PubMed Web of Science ®Google Scholar